GlassScriptPhysician profile
Nicholas Roditis
NPI 1932104494
$6,501.60
in general payments reported to CMS, 2019-2025
20 companies · $2,134 in 2025
The $2,134 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $230 · 2021: $880 · 2022: $821 · 2023: $833 · 2024: $1,112 · 2025: $2,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,981 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,980.90 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,841.49 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Abbvie INC. | $892.26 | 2019-2025 | Linzess |
| Madrigal Pharmaceuticals | $586.77 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $556.64 | 2023-2025 | Tremfya, Stelara, Remicade |
| E.R. Squibb & Sons, L.L.C. | $387.87 | 2023 | Zeposia |
| Gilead Sciences, INC. | $370.46 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $355.17 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $296.69 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $222.25 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $215.04 | 2021-2025 | Entyvio |
| Ferring Pharmaceuticals INC. | $213.38 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $181.99 | 2021-2025 | Linzess |
| Medtronic, INC. | $110.96 | 2025 | Interstim |
| Anx Robotica Corp | $75.48 | 2025 | |
| Allergan, INC. | $49.80 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $48.58 | 2025 | Wegovy |
| Cumberland Pharmaceuticals, INC. | $36.06 | 2021-2022 | |
| Braintree Laboratories, INC. | $23.91 | 2024 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $20.30 | 2019 | |
| Celgene Corporation | $16.50 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Roditis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.